Genmab to Highlight Advances Across Its Oncology Portfolio at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2026 Congress
Genmab will present 23 abstracts at the 2026 ASCO and EHA meetings, with 20 focused on its approved bispecific antibody epcoritamab (EPKINLY). Key data includes the full results from the Phase 3 EPCORE DLBCL-1 trial comparing epcoritamab monotherapy to chemotherapy in relapsed/refractory large B-cell lymphoma, and data from the Phase 3 EPCORE FL-1 trial in follicular lymphoma.
Key figures
- Drug Name
- epcoritamab
- Phase Of Trial
- Phase 3
- Abstract count
- 23
- Oral presentations
- 4
- Epcoritamab abstracts
- 20
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.